Latest Medical Device Sector News

ImpediMed has revamped its leadership with two new commercial roles and reported encouraging sales momentum for its SOZO device. The company is advancing clinical trials and expanding its presence in cancer survivorship, weight management, and heart health sectors.

Osteopore has secured Hainan FDA approval to clinically use and sell its custom orthopaedic devices at Shanghai Ruijin Hospital’s Hainan branch, marking a key step towards wider China market access. The company has scheduled its first patient surgery for June 2026.

Compumedics maintains robust sales momentum but faces FY26 revenue timing challenges due to MEG installation delays and a cautious Somfit D rollout. The company expects solid year-on-year growth and positions for improved execution in FY27.

Anteris Technologies Global Corp. posted a $94.2 million loss for 2025 amid a 29% revenue decline, while progressing its pivotal DurAVR THV clinical trial and securing $320 million in early 2026 financings.

SomnoMed Limited has reported a return to profitability for the half-year ending December 2025, posting a $792,000 net profit after tax on the back of a 13% revenue increase. Despite the positive turnaround, the company has elected not to pay an interim dividend.

Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.

OncoSil Medical has reported a record quarter for dose sales alongside key European market entries and a successful manufacturing milestone, signalling growing momentum for its pancreatic cancer treatment.

Nova Eye Medical has reported a record US$6.1 million in sales for the December 2025 quarter, driven by strong US demand and a 24% annual growth rate that outpaces the industry.

Epiminder Limited has settled a $15.77 million tax liability with the ATO related to historical R&D claims, freeing up $4.23 million from IPO proceeds for working capital.

EBR Systems has expanded its intellectual property holdings with four new patents, reinforcing its lead in wireless cardiac pacing technology, while facing a preliminary setback on a patent term extension application.

ResMed Inc has updated the foreign exchange rate for its upcoming dividend payable to ASX CDI holders, impacting the Australian dollar amount investors will receive.

Orthocell has completed its first Remplir™ surgical case in Hong Kong, marking a pivotal step in its Asian commercialisation strategy. The launch at the Hong Kong Orthopaedic Association Congress and partnership with MontsMed set the stage for broader regional growth.